8-K: Amgen Reports Strong 2025 Growth Amidst Market Shifts

Amgen announced robust double-digit revenue and EPS growth for 2025, while providing 2026 guidance and detailing pipeline advancements and competitive challenges.

Summary

• Total revenues increased 9% to $9.9 billion in the fourth quarter of 2025 and 10% to $36.8 billion for the full year 2025.
• Product sales grew 7% in Q4 and 10% for the full year, driven by volume growth (10% in Q4, 13% for full year), partially offset by 4% and 3% lower net selling prices, respectively.
• GAAP earnings per share (EPS) increased 111% to $2.45 in Q4 and 88% to $14.23 for the full year, benefiting from higher revenues and lower net unrealized losses on equity investments, partially offset by higher operating expenses.
• Full year 2025 GAAP EPS included a $1.2 billion Otezla intangible asset impairment charge following its selection for Medicare price setting as part of the Inflation Reduction Act (IRA).
• Non-GAAP EPS for the full year increased 10% to $21.84, while Q4 non-GAAP EPS remained relatively unchanged at $5.29.
• Free cash flow for the full year 2025 was $8.1 billion, a decrease from $10.4 billion in 2024, primarily due to timing of working capital (collections) and higher capital expenditures.
• The company retired $6.0 billion of debt for the full year 2025.
• 2026 guidance projects total revenues in the range of $37.0 billion to $38.4 billion, GAAP EPS of $15.45 to $16.94, and non-GAAP EPS of $21.60 to $23.00.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating strong underlying business performance and pipeline progress, despite significant headwinds from the IRA and biosimilar competition. The growth in key products and promising GLP-1 data are strong positives.

Positives

• Total revenues increased 9% to $9.9 billion in Q4 2025 and 10% to $36.8 billion for the full year 2025.
• Product sales grew 7% in Q4 and 10% for the full year, driven by strong volume growth (10% in Q4, 13% for full year).
• Eighteen products achieved record sales for the full year 2025, and fourteen products exceeded one billion dollars in annual sales.
• Thirteen products delivered at least double-digit sales growth for the full year.
• GAAP EPS increased 111% to $2.45 in Q4 and 88% to $14.23 for the full year, driven by higher revenues and net unrealized gains on equity investments.
• GAAP operating income increased from $2.3 billion to $2.7 billion in Q4 and from $7.3 billion to $9.1 billion for the full year.
• GAAP operating margin increased 2.5 percentage points to 29.0% in Q4 and 3.1 percentage points to 25.8% for the full year.
• Repatha sales increased 44% year-over-year to $870 million in Q4 and 36% for the full year, driven by volume growth.
• EVENITY sales increased 39% year-over-year to $599 million in Q4 and 34% for the full year, primarily driven by volume growth.
• UPLIZNA sales increased 131% year-over-year to $233 million in Q4 and 73% for the full year, primarily driven by volume growth.
• TEZSPIRE sales increased 60% year-over-year to $474 million in Q4 and 52% for the full year, driven by volume growth.
• IMDELLTRA/IMDYLLTRA generated $234 million of sales in Q4 and $627 million for the full year, with Q4 sales increasing 31% quarter-over-quarter.
• Positive Phase 2 study results for MariTide in chronic weight management showed sustained weight loss, good tolerability, and improved cardiometabolic parameters.
• MariTide Phase 2 study in Type 2 Diabetes demonstrated robust and clinically meaningful reductions in HbA1c and weight.
• Repatha's VESALIUS-CV clinical trial showed a 25% relative reduction in the risk of 3-P MACE and a 36% reduction in heart attack risk.
• UPLIZNA received European Commission approval for IgG4-RD and FDA approval for generalized myasthenia gravis (gMG).
• Daxdilimab Phase 2 study met primary and key secondary endpoints in primary discoid lupus erythematosus (DLE) with an acceptable safety and tolerability profile.
• IMDELLTRA received full FDA approval for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC).
• The company retired $6.0 billion of debt for the full year 2025.
• Declared a Q4 2025 dividend of $2.38 per share, representing a 6% increase from the same period in 2024.

Negatives

• Net selling price declined by 4% in Q4 2025 and 3% for the full year 2025.
• Otezla intangible asset impairment charges of $1.2 billion were recorded in 2025 due to Medicare price setting under the Inflation Reduction Act (IRA).
• Non-GAAP EPS remained relatively unchanged from $5.31 to $5.29 for the fourth quarter.
• Non-GAAP operating margin decreased 3.5 percentage points to 42.8% in Q4 and 0.8 percentage points to 46.1% for the full year.
• Free cash flow decreased to $8.1 billion for the full year 2025 from $10.4 billion in 2024, driven by timing of working capital (collections) and higher capital expenditures.
• Prolia sales decreased 10% year-over-year in Q4, driven by 8% lower net selling price and decreased volume. Accelerated sales erosion is expected in 2026 due to increased biosimilar competition.
• Ultra-Rare products sales decreased 27% year-over-year in Q4 and 5% for the full year, primarily driven by generic competition for RAVICTI, with continued erosion expected in 2026.
• Enbrel sales decreased 48% year-over-year in Q4 and 33% for the full year, primarily due to 35-36% lower net selling price resulting from the U.S. Medicare Part D redesign and increased 340B Program mix.
• AMJEVITA/AMGEVITA sales decreased 41% year-over-year in Q4 and 22% for the full year, primarily driven by lower volume.
• KYPROLIS sales decreased 6% year-over-year in Q4 and for the full year, primarily driven by lower volume.
• XGEVA sales decreased 20% year-over-year in Q4 and 6% for the full year, primarily driven by lower volume. Accelerated sales erosion is expected in 2026 due to increased biosimilar competition.
• The company will terminate the rocatinlimab development and commercialization collaboration with Kyowa Kirin as part of portfolio prioritization.
• The U.S. FDA requested ChemoCentryx (an Amgen subsidiary) to voluntarily withdraw TAVNEOS from the U.S. market due to concerns about the re-adjudication process of primary endpoint results and hepatotoxicity risk, though Amgen does not intend to withdraw.
• Does not intend to pursue regulatory approval for bemarituzumab in first-line gastric cancer based on Phase 3 study data, and stopped the FORTITUDE-103 study.

Risks

• Impact of the Inflation Reduction Act (IRA) on product pricing and asset valuations, as evidenced by the $1.2 billion Otezla intangible asset impairment.
• Increased competition from biosimilars and generics, leading to accelerated sales erosion for established products like Prolia, XGEVA, RAVICTI, and Enbrel.
• Lower net selling prices across the product portfolio impacting overall revenue growth.
• Fluctuations in free cash flow due to timing of working capital, primarily collections, and higher capital expenditures.
• Regulatory challenges and potential market withdrawals, such as the FDA's request for TAVNEOS withdrawal, despite Amgen's confidence in its benefit-risk profile.
• Dependence on a few key manufacturing facilities and third-party manufacturers, which could lead to supply constraints.
• Exposure to global economic conditions, geopolitical relations, and government actions affecting business operations.
• Pricing pressure, political and public scrutiny, and reimbursement policies imposed by third-party payers.
• Challenges to patent protection, which could lead to competitors invalidating or circumventing patents.
• Risks associated with collaborations and acquisitions, including the potential for unanticipated costs, delays, or failure to realize benefits (e.g., rocatinlimab collaboration termination).
• Potential for cyberattacks or information security breaches compromising systems and data.
• Volatility of the company's stock price due to various market events.
• Negative impact on business and operations from failure to achieve sustainability objectives or effects of global climate change and natural disasters.
• Inability to access capital and credit markets on favorable terms.

Future Outlook

Amgen expects total revenues for the full year 2026 to be in the range of $37.0 billion to $38.4 billion. GAAP EPS is projected between $15.45 and $16.94, with a tax rate in the range of 15.5% to 17.0%. Non-GAAP EPS is guided to be $21.60 to $23.00, with a tax rate of 16.0% to 17.5%. Capital expenditures are anticipated to be approximately $2.6 billion, and share repurchases are not expected to exceed $3 billion. The company also anticipates accelerated sales erosion for Prolia and XGEVA in 2026 due to increased biosimilar competition and continued RAVICTI sales erosion from generic competition.

Management Comments

• "Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth." Robert A. Bradway, chairman and chief executive officer.
• Amgen is confident that TAVNEOS demonstrates effectiveness and a favorable benefit-risk profile, despite the FDA's request for voluntary withdrawal.

Industry Context

StockSavvy.ai notes that Amgen's strong 2025 performance, particularly in revenue and non-GAAP EPS, demonstrates resilience in a challenging pharmaceutical landscape. The significant growth in key products like Repatha, EVENITY, UPLIZNA, and TEZSPIRE highlights successful market penetration and demand for innovative therapies, especially in cardiovascular, rare disease, and inflammation segments. However, the $1.2 billion Otezla impairment charge underscores the increasing impact of U.S. government policies like the Inflation Reduction Act on drug pricing and asset valuations. The accelerated sales erosion expected for Prolia, XGEVA, and RAVICTI due to biosimilar and generic competition reflects a broader industry trend where established biologics face significant pressure, necessitating continuous pipeline innovation. The robust R&D investment, particularly in MariTide (GLP-1), positions Amgen to compete in the rapidly expanding obesity and diabetes markets, a critical area for future growth. The regulatory challenge with TAVNEOS also highlights the ongoing scrutiny and complexities in drug approvals and post-market surveillance.

Comparison to Industry Standards

• Amgen's double-digit revenue growth (10% for FY25) is strong for a large-cap biopharmaceutical company, often exceeding the average growth rates of mature pharmaceutical companies which typically range from low to mid-single digits. For example, competitors like Pfizer and Bristol Myers Squibb have faced revenue declines or modest growth in recent periods due to patent expirations and pipeline challenges.
• The $1.2 billion Otezla intangible asset impairment due to Medicare price setting under the IRA is a significant event, reflecting the direct financial impact of new U.S. healthcare legislation. This is a trend that other pharmaceutical companies with high-cost drugs, such as Eli Lilly (for Mounjaro/Zepbound) and Novo Nordisk (for Ozempic/Wegovy), are also closely monitoring, as the IRA's impact on pricing power is a major industry concern.
• The accelerated sales erosion for Prolia and XGEVA in 2026 due to biosimilar competition is consistent with the broader industry trend seen with other blockbuster biologics. For instance, Humira (AbbVie) has experienced substantial sales declines following the entry of multiple biosimilars, and Enbrel (Amgen's own product) has already seen significant price erosion (35-36% lower net selling price in 2025) due to market dynamics and the 340B Program.
• Amgen's investment in MariTide (GLP-1/GIPR) positions it in a highly competitive and rapidly growing market, currently dominated by Novo Nordisk's Wegovy/Ozempic and Eli Lilly's Zepbound/Mounjaro. The positive Phase 2 results for MariTide suggest Amgen could become a significant player, but it faces a high bar set by the efficacy and safety profiles of existing market leaders.
• The 6% increase in the Q4 2025 dividend demonstrates a commitment to shareholder returns, which is a common practice among established pharmaceutical companies with strong cash flows, such as Johnson & Johnson and Merck, who consistently raise dividends.

Legal Proceedings

• Otezla intangible asset impairment charges of $1.2 billion were recorded in 2025, following its selection for Medicare price setting as part of the Inflation Reduction Act (IRA).
• The FDA requested ChemoCentryx (an Amgen subsidiary) to voluntarily withdraw TAVNEOS from the U.S. market due to concerns about the re-adjudication process of primary endpoint results for 9 of 331 patients in its pivotal clinical trial and hepatotoxicity risk. Amgen informed the Agency it did not intend to withdraw TAVNEOS and is evaluating next steps.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and EPS growth, increased dividend, and debt reduction. Negative impact from Otezla impairment and potential TAVNEOS market withdrawal.
• Patients: Continued access to innovative medicines, with new approvals for UPLIZNA and full approval for IMDELLTRA. Potential impact on TAVNEOS patients depending on FDA resolution.
• Employees: Continued investment in R&D and pipeline suggests stability and growth opportunities.
• Competitors: Amgen's strong performance and pipeline advancements (e.g., MariTide) indicate robust competition in key therapeutic areas. Biosimilar and generic competition continues to impact Amgen's established products, affecting competitors in similar ways.
• Regulatory Authorities: Ongoing engagement with FDA regarding TAVNEOS and compliance with the Inflation Reduction Act.

Next Steps

• Expect net selling price for Repatha to decline by roughly mid-single digits in 2026.
• Expect accelerated sales erosion for Prolia in 2026 due to increased competition from multiple biosimilars.
• Expect continued RAVICTI sales erosion in 2026 due to generic competition.
• Expect Enbrel, Otezla, KRYSTEXXA, TEZSPIRE, and Repatha to follow historical pattern of lower sales in Q1 relative to subsequent quarters due to benefit plan changes, insurance reverification, and increased co-pay expenses.
• Further analysis from Repatha's VESALIUS-CV trial on patients without significant atherosclerosis to be presented at the American College of Cardiology in March 2026.
• Initiate Phase 3 studies of MariTide in people living with Type 2 Diabetes in 2026.
• Initiate Phase 3 studies of UPLIZNA in patients with autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy in 2026.
• Expected completion of TEPEZZA subcutaneous administration study in H2 2026.
• Evaluating next steps with the FDA regarding TAVNEOS, while keeping patient safety, needs, and support at the forefront.
• Expected completion of dazodalibep Sjogren's disease studies in H2 2026.
• Expected completion of TEZSPIRE eosinophilic esophagitis study in H2 2026.
• Expected completion of AMG 104 asthma study in H1 2026.
• Kyowa Kirin will assume ownership and responsibility for the rocatinlimab program, with Amgen providing certain transition services.
• Share repurchases not to exceed $3 billion in 2026.

Key Dates

Recommendation

Amgen delivered strong financial results for 2025 with double-digit revenue and non-GAAP EPS growth, demonstrating robust underlying business performance driven by volume growth across a broad portfolio of innovative medicines. The company's pipeline, particularly MariTide in the high-growth obesity and diabetes markets, shows significant promise with positive Phase 2 data and planned Phase 3 initiation. While facing headwinds from biosimilar competition for established products and the impact of the IRA on Otezla, Amgen's ability to grow revenue and EPS, reduce debt, and increase dividends signals financial strength and effective strategic execution. The 2026 guidance, while factoring in some competitive pressures, still projects continued revenue and EPS growth, making it an attractive long-term investment for a seasoned investor.

Keywords

Amgen, AMGN, Earnings, Financial Results, Biotechnology, Pharmaceutical, Revenue Growth, EPS, Free Cash Flow, Pipeline, MariTide, GLP-1, Obesity, Diabetes, Repatha, UPLIZNA, TEZSPIRE, Otezla, Enbrel, Biosimilars, Inflation Reduction Act, IRA, TAVNEOS, FDA, Oncology, Rare Disease, Inflammation, Cardiovascular, SCLC, IMDELLTRA, R&D, Debt, Dividend